The meeting is set to focus on advancing smoking cessation.
Qnovia Inc. CEO Brian Quigly will speak publicly at a joint meeting with the FDA and NIH as part of the Advancing Smoking Cessation campaign.1
In a press release, Quigley said, “I am encouraged by the opportunities recently outlined by FDA and NIH for pursuing innovation in smoking cessation, an area with no new therapies approved in several decades. A modernization of the approach to smoking cessation medicines is overdue, and I am hopeful today's discussion will lead to more innovation in the industry.”
He continued, “The currently available nicotine replacement therapies (NRTs) deliver nicotine buccally or transdermally, resulting in suboptimal nicotine concentrations and ultimately a failure to provide relief from cravings or withdrawals in the real world. We believe an NRT that safely delivers pharmaceutical grade nicotine using the pulmonary route of administration can address the shortcomings of existing therapies. We are committed to directly addressing this unmet public health need through the development of our lead asset QN-01, a prescription inhaled smoking cessation therapy. We will be advancing QN-01 through Phase 1 clinical trials this year and are committed to continuing to engage with regulators as we advance through the regulatory process in both the U.S. and U.K."
Qnovia recently announced FDA clearance of its IND application for the RespiRX Nicotine Inhaler as a prescription therapy for quitting smoking.2 The company will begin Phase 1 studies on the device.
In a press release issued at the time, Quigley said, “The FDA clearance of our IND application for QN-01 marks a significant achievement for Qnovia as we transition to a clinical-stage therapeutics company. Our U.S. clinical development plan is de-risked by the positive first-in-human data we generated last year in support of advancing QN-01 in the United Kingdom where we demonstrated pulmonary delivery and a superior pharmacokinetic profile for the RespiRx when compared to existing nicotine replacement therapies. The next step for our U.S. program is to initiate a randomized Phase 1 trial that evaluates QN-01 compared to the Nicotrol® Inhaler and combustible cigarettes in a head-to-head comparison. We remain on track to dose our first patient in the fourth quarter of 2024 and in parallel will be advancing to a pivotal clinical trial in the UK to support an MAA submission to the MHRA in 2026."
Qnovia policy and regulatory strategy advisor Mitch Zeller also said, “There have been no treatment options for smoking cessation approved in the U.S. in over 20 years. As a result, attempting to quit 'cold turkey' remains the most popular method of quitting smoking. There is an extraordinary public health need for truly innovative products to help health-concerned smokers stop using cigarettes. Any effort to reduce the death and disease caused by tobacco use must include new and better tools in the treatment toolkit.”
Mario Danek, founder and chief technology officer at Qnovia added, “Qnovia's platform for inhaled drug delivery is purpose fit to address this unmet need and we are proud to lead the charge in encouraging the innovation and development of safe and effective pharmacotherapies to help the millions of smokers who are trying to quit smoking. We believe our proprietary drug delivery platform has the potential to be a highly differentiated treatment option not only for treatment of nicotine dependence but for a wide variety of treatments that would benefit from inhaled drug delivery.”
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
AbbVie’s Emraclidine Fails to Reduce Schizophrenia Symptoms Compared to Placebo
November 11th 2024Results from the Phase II EMPOWER trial found that emraclidine failed to meet its primary endpoint of reducing Positive and Negative Syndrome Scale scores after six weeks of treatment for schizophrenia.